References
- Barret-Connor E. Hormonal replacement therapy. Br Med J 1998;317:457–61
- Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy. Lancet 1997;350:1047–59
- Magnusson C, Baron J, Correia N, et al. Breast cancer risk following long-term estrogen and estrogen—progestin replacement therapy. Int J Cancer 1999;81:339–44
- Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen—progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000;283:485–91
- Ross RK, Paganini-Hill A, Wan PC, et al. Effect of hormonal replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328–32
- Speroff L. Postmenopausal estrogen—progestin therapy and breast cancer: a clinical response to epidemiological reports. Climacteric 2000;3: 3–12
- Preston-Martin S, Pike MC, Ross RK, et al. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415–21
- Key TJ, Pike MC. The dose—effect relationship between 'unopposed' estrogens and endometrial mitotic rate: its central role in explaining and pre-dicting endometrial cancer risk. Br J Cancer 1988;57:205–12
- Gompel A, Malet C, Spritzer P, et al. Progestin effect on cell proliferation and 1713-hydroxy-steroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab 1986;63:1174–80
- Longacre TA, Bartow SA. A correlative morpho-logic study of human breast and endometrium in the menstrual cycle. Am J Surg Patbol 1986;10: 382–93
- Söderqvist G, Isaksson E, Von Schoultz B, et al. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 1997;176:123–8
- Franzen S, Zajicek J. Aspiration biopsy in diagno-sis of palpable lesions of the breast. Acta Radiol 1968;7:241–62
- Skoog L, Humla S, Isaksson S, et al. Immuno-cytochemical analusis of receptors for estrogen and progesterone in fine needle aspirates from human mammary carcinomas. Diagn Cytopatbol 1990;6:95–8
- Gerdes J, Li L, Schlueter C, et al. Immuno-biochemical and molecular biologic character-ization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Patbol 1991;138:867–73
- Söderqvist G, Von Schoultz B, Tani E, et al. Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. Am J Obstet Gynecol 1993;168:874–9
- Isaksson E, Von Schoultz E, Odlind V, et al. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001; in press
- Reid SE, Murthy MS, Kaufman M, et al. Endo-crine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br J Surg 1996;83:1037–46
- Costa MJ, Tadros T, Hilton G, et al. Breast fine needle aspiration cytology. Utility as a screening tool for clinically palpable lesions. Acta Cytol 1993;37:461–71
- Skoog L, Rutqvist LE, Wilking N. Analysis of hormone receptors and proliferation fraction in fine-needle aspirates from primary breast carcinomas during chemotherapy or tamoxifen treatment. Acta Oncol 1992;31:139–41
- Maygarden SJ, McCall JB, Frable WJ. Fine needle aspiration of breast lesions in women aged 30 and under. Acta Cytol 1991;35: 687–94
- Nicastri GR, Reed WP, Dziura BR. The accuracy of malignant diagnoses established by fine needle aspiration cytologic procedures of mammary masses. Surg Gynecol Obstet 1991;172:457–60
- Saftlas AF, Hoover RN, Brinton LA, et al. Mammographic densities and risk of breast cancer. Cancer 1991;67:2833–8
- Boyd NF, Lockwood GA, Byng JW, et al. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomark Prey 1998;7: 1133–44
- Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen—progestin on mammo-graphic parenchymal density. Ann Intern Med 1999;130:262–9
- Lundström E, Wilczek B, Von Palffy Z, et al. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1991;181: 348–53
- Hesch RD, Kenemans P. Hormonal prevention of breast cancer: proposal for a change in paradigm. Br J Obstet Gynaecol 1999;106:1006–18